← boardnext 2026-12next 2027-09next 2028-08-31
KARD
Kardigan, Inc.distress 3/10 · well-funded / low risk$22.52-1%today-13% from 52w high
Cardiovascular 1
Lead: Hypertension · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$287M
Runway
1.9 yrs
Shares 1y
—
Price & events
+2.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+7.2%
1W
+1.3%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
+2.4%
All
Overview
- Volume
- 12.18K
- 52 Week Range
- $21.02 – $25.90
- Float Shares
- 34.28M
- Short %
- 1.94%
- % Held by Insiders
- 34.97%
- % Held by Institutions
- 26.02%
- RVOL
- 0.02x
Pipeline stages · 3 programs
Tonlamarsen
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
danicamtiv
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ataciguat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | Tonlamarsen | Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 2/3 | danicamtiv | Symptomatic Genetic Dilated Cardiomyopathy | — | recruiting |
| 2028-08-31 Estimated 50% readout ~2028-11-14 | Phase 2/3 | Ataciguat | Moderate Aortic Valve Stenosis | — | recruiting |
| 2026-01-12 | Phase 2 | Tonlamarsen | Hypertension | 206 | completed |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $44 (+93% upside) · 4 analysts
- 2026-07-13TD CowenBuy
- 2026-07-13Leerink PartnersOutperform
- 2026-07-13JP MorganOverweight
- 2026-07-13JefferiesBuy
Competitors — Hypertension
- LLYELI LILLY & Co$1094.4B · D3
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- INSMINSMED Inc$22.9B · D2
- MLYSMineralys Therapeutics, Inc.$2.1B · D6
- SGPSpyGlass Pharma, Inc.$682M · D2
- TECXTectonic Therapeutic, Inc.$589M · D0
- IKTInhibikase Therapeutics, Inc.$289M · D4
- GALTGALECTIN THERAPEUTICS INC$231M · D5
- GOSSGossamer Bio, Inc.$33M · D5
Recent news
- 2026-07-20Price to earnings ratio of Kardigan, Inc. – NASDAQ:KARD - TradingView
- 2026-07-16Kardigan, Inc. (NASDAQ:KARD) Short Interest Up ∞ in June - MarketBeat
- 2026-07-15Kardigan, Inc.: Target Price Consensus and Analysts Recommendations | KARD | US4859251013 - marketscreener.com
- 2026-07-13Kardigan (KARD) grants 20,706 RSUs tied to Perceptive-linked director pay - Stock Titan
- 2026-07-13KARD Initiated Coverage by TD Cowen -- Price Target Announced at $46 - GuruFocus
- 2026-07-13KARD News & Events - Intellectia AI
- 2026-07-13KARD Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
- 2026-07-13Jefferies initiates Kardigan stock with buy rating on cardiology pipeline By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.